TPOXX® Antiviral Treatment (Tecovirimat)

CPV: Antivirals for systemic use

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

3 Nov 2022, 17:23 GMT

Last source update

3 Nov 2022, 17:23 GMT

Authority reference

C79951

FTS notice number

2022/S 000-031159

Classification (CPV)

Antivirals for systemic use

Delivery area

UK

Official registry OCID

ocds-h6vhtk-037efd Find a Tender

Why no open competition

The procurement falls outside the scope of application of the directive

Published justification

Negotiated procedure without a notice:<br/><br/>Regulation 32(2)(b)(ii)<br/><br/>This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of monkeypox in the UK.<br/><br/>The procurement was initiated on the basis that Regulation 32(2)(b)(ii) was applicable in the circumstances that prevailed. This permits the use of a direct award where competition is absent for technical reasons. That is the situation that applies here and as a result a competitive procurement exercise could not have been conducted.<br/><br/>The monkeypox virus belongs to a family of viruses called orthopox viruses. The drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. There was no reasonable alternative or substitute available to the authority. This antiviral is the only product with authorisation from the MHRA for the treatment of monkeypox and Meridian Medical Technologies has exclusive right to supply the product to the UK. Therefore, this was the only option available within the market for the UK to procure an effective treatment against the current monkeypox outbreak.

Publisher note: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate the price per dose. Publication of this information would therefore: (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors; and (iii) impact fair competition between vendors.

• MERIDIAN MEDICAL TECHNOLOGIES LIMITEDAwarded supplierNI020416 Forsyth House, Cromac Square, Belfast, Co. Antrim, BT2 8LA, Belfast, Northern Ireland, BT2 8LA

No document links were published on the notice.